NOTV - Inotiv, Inc.
Pre-Market:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 5.81 |
| Open | 5.98 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 5.79 - 6.07 |
| 52 Week Range | 3.65 - 27.22 |
| Volume | |
| Avg. Volume | 378,849 |
| Market Cap | 154.302M |
| Beta (5Y Monthly) | 2.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.59 |
| Earnings Date | Aug 08, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.08 |
Fair Value
Related Research
ZacksHere Is Why Bargain Hunters Would Love Fast-paced Mover Inotiv, Inc. (NOTV)
Inotiv, Inc. (NOTV) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
GlobeNewswireInotiv, Inc. to Present at Jefferies 2023 Healthcare Conference
WEST LAFAYETTE, Ind., May 25, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will present at the Jefferies Healthcare Conference, being held in New Yor
- GlobeNewswire
Inotiv, Inc. to Participate in May Investor Conferences
WEST LAFAYETTE, Ind., May 19, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today its participation in the following investor conferences: Benchmark Healthcare House Call Conference (Virtual)One-on-one meetings: May 23, 2023 Craig-Hallum Institutional Investor C
ZacksWall Street Analysts Predict a 168.98% Upside in Inotiv, Inc. (NOTV): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 169% in Inotiv, Inc. (NOTV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Simply Wall St.Inotiv Second Quarter 2023 Earnings: Beats Expectations
Inotiv ( NASDAQ:NOTV ) Second Quarter 2023 Results Key Financial Results Revenue: US$151.5m (up 7.9% from 2Q 2022). Net...
ZacksInotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates
Inotiv, Inc. (NOTV) delivered earnings and revenue surprises of -112.50% and 13.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Inotiv, Inc. Announces Second Quarter Fiscal 2023 Financial Results
Updates Select Full Year Fiscal 2023 Financial GuidanceWEST LAFAYETTE, Ind., May 11, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q2 FY 2023”) and six months (“YTD FY 2023”) ended March 31, 2023. Financial Highligh
- Simply Wall St.
Inotiv's (NASDAQ:NOTV) investors will be pleased with their splendid 235% return over the last five years
While Inotiv, Inc. ( NASDAQ:NOTV ) shareholders are probably generally happy, the stock hasn't had particularly good...
Zacks4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?
4D Molecular Therapeutics, Inc. (FDMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- GlobeNewswire
Inotiv, Inc. Expands Safety Pharmacology Offering to Include Cardiopulmonary Telemetry
WEST LAFAYETTE, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, and research models and related products and services, announced today the expansion of the Company’s safety pharmacology offering with the validation and verification of a cardiopulmonary telemetry study model in cynomolgus macaques. Offered through Inotiv’s Discovery and Safety Assessment
- GlobeNewswire
Inotiv, Inc. to Report Fiscal 2023 Second Quarter Financial Results and Host Conference Call on Thursday, May 11, 2023
WEST LAFAYETTE, Ind., April 26, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, on Thursday, May 11, 2023, after the close of the stock market. The Company will
PR NewswireInotiv Applauded by Frost & Sullivan as Key Competitor in the Bio-analytical Testing Services Market
Recently, Frost & Sullivan assessed the bio-analytical testing services industry and, based on its findings, recognized Inotiv, Inc. (Nasdaq: NOTV) with the 2022 North American Customer Value Leadership Award. Inotiv addresses the needs of bio-analytical, non-clinical, and clinical research drug and device developers by operating in contract research services and research product business segments. It offers a range of experienced scientists and state of the art facilities to provide highly comp
- Simply Wall St.
Great news for Inotiv, Inc. (NASDAQ:NOTV): Insiders acquired stock in large numbers last year
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
ZacksImplied Volatility Surging for Inotiv (NOTV) Stock Options
Investors need to pay close attention to Inotiv (NOTV) stock based on the movements in the options market lately.
Insider MonkeyHere’s Why Inotiv (NOTV) Declined in Q4
Wasatch Global Investors, an asset management company, released its “Wasatch Micro Cap Growth—U.S. Strategy” fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy declined and underperformed its benchmark, the Russell Microcap Index in the fourth quarter, which gained 4.72%. The disappointing returns in industrials, financials, and consumer discretionary were the […]
- Simply Wall St.
Inotiv, Inc.'s (NASDAQ:NOTV) 20% loss last week hit both individual investors who own 40% as well as institutions
Key Insights The considerable ownership by individual investors in Inotiv indicates that they collectively have a...
Insider MonkeyInotiv, Inc. (NASDAQ:NOTV) Q1 2023 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV) Q1 2023 Earnings Call Transcript February 13, 2023 Operator: Hello, and welcome to Inotiv Inc.’s First Quarter Fiscal 2023 Financial Results Conference Call and Webcast. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It’s now my pleasure to turn the call over to Devin […]
- GlobeNewswire
Inotiv, Inc. Announces First Quarter Fiscal 2023 Financial Results
Reiterates Select Full Year Fiscal 2023 Financial GuidanceWEST LAFAYETTE, Ind., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q1 FY 2023”) ended December 31, 2022. Financial Highlights Q1 FY 2023 Highlights
- GlobeNewswire
Inotiv, Inc. to Report Fiscal 2023 First Quarter Financial Results and Host Conference Call on Monday, February 13, 2023
WEST LAFAYETTE, Ind., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022 on Monday, February 13, 2023 after the close of the stock market. The Company wi
- GlobeNewswire
Inotiv Selected as a Winner of the 2023 Top Workplaces USA Award
WEST LAFAYETTE, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that it has earned the 2023 Top Workplaces USA award, issued by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplac
- GlobeNewswire
Inotiv, Inc. Announces Changes to Board of Directors
WEST LAFAYETTE, Ind., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that David Landman has been designated by Jermyn Street Associates LLC as its Shareholder Representative on the Board of Directors, replacing Scott Cragg, who is stepping down to
Insider MonkeyInotiv, Inc. (NASDAQ:NOTV) Q4 2022 Earnings Call Transcript
Inotiv, Inc. (NASDAQ:NOTV) Q4 2022 Earnings Call Transcript January 10, 2023 Inotiv, Inc. beats earnings expectations. Reported EPS is $-0.32, expectations were $-0.37. Operator: Greetings, and welcome to the Inotiv, Inc.’s Fourth Quarter and Full Year Fiscal 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer […]
- GlobeNewswire
Inotiv, Inc. Announces Fourth Quarter and Full Year Fiscal 2022 Financial Results
Provides Select First Quarter and Full Year Fiscal 2023 Financial GuidanceWEST LAFAYETTE, Ind., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q4 FY 2022”) and twelve months (“FY 2022”) ended September 30, 2
- GlobeNewswire
Inotiv, Inc. to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results and Host Conference Call on Tuesday, January 10, 2023
WEST LAFAYETTE, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 fourth quarter and full year ended September 30, 2022 on Tuesday, January 10, 2023 after the cl
Insider Monkey10 Stocks Under $20 to Buy Now
In this article, we discuss the 10 stocks under $20 to buy now. If you want to read about some more high potential stocks, go directly to 5 Stocks Under $20 to Buy Now. In an era of soaring market valuations, cheap stocks offer investors from across the spectrum a healthy chance to make handsome […]